$2.57 Billion is the total value of Tekla Capital Management LLC's 187 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 110.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KPTI | Exit | Karyopharm Therapeutics Inc. | $0 | – | -20 | -100.0% | 0.00% | – |
| ZFGN | Exit | Zafgen, Inc. | $0 | – | -13,307 | -100.0% | -0.00% | – |
| EARS | Exit | Auris Medical Holding AG | $0 | – | -774,504 | -100.0% | -0.02% | – |
| IPXL | Exit | Impax Laboratories, Inc. | $0 | – | -124,335 | -100.0% | -0.08% | – |
| BCRX | Exit | BioCryst Pharmaceuticals, Inc. | $0 | – | -449,255 | -100.0% | -0.08% | – |
| ADVM | Exit | Adverum Biotechnologies, Inc. | $0 | – | -743,974 | -100.0% | -0.10% | – |
| CASC | Exit | Cascadian Therapeutics, Inc. | $0 | – | -740,769 | -100.0% | -0.11% | – |
| AGNPRA | Exit | Allergan plc5.50% convertible preferred series a | $0 | – | -5,000 | -100.0% | -0.11% | – |
| DXCM | Exit | DexCom, Inc. | $0 | – | -53,950 | -100.0% | -0.12% | – |
| Exit | Intercept Pharmaceuticals, Inc.note 3.250% 7/1/23 | $0 | – | -6,900,000 | -100.0% | -0.21% | – | |
| NUVA | Exit | NuVasive, Inc. | $0 | – | -117,437 | -100.0% | -0.26% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.